National Kynmobi (sublingual apomorphine HCl) Webinar: Using Kynmobi in Practice


This national webinar brings together leading experts to share critical insights on optimising Parkinson's disease
management. The sessions focus on the practical application of advanced therapies, clinical recognition of intermittent "OFF" episodes, and real-world evidence from UK clinical practice. Watch the videos from the webinar all on this webpage.

Prescribing Information (PI) is available by clicking on the PI buttons in this page

Webinar overview

Gain exclusive access to insights from expert speakers as they explore pharmacological approaches, clinical recognition of intermittent "OFF" episodes, and practical implementation in Parkinson's disease.

This webinar brings together specialists to share essential clinical insights, focusing on exploiting dopamine pharmacology in Parkinson’s disease, evaluating the efficacy and safety of "OFF" episode management, and implementing practical initiation strategies drawn from UK clinical experience.

What You’ll Learn:

  • Exploiting Dopamine Pharmacology in Parkinson’s Disease: Deepen your understanding of targeted pharmacological approaches and dopamine pathways.

  • Efficacy and Safety: Gain clinical insights into "OFF" episode management to improve clinical recognition and patient outcomes.

  • Practical Strategies for Initiation and UK Experience: Discover real-world implementation strategies and clinical insights from UK practice.

About Kynmobi (apomorphine hydrochloride)
Kynmobi is a sublingual formulation of apomorphine indicated for the intermittent treatment of ‘OFF’ episodes in adult patients with Parkinson’s disease, which are not sufficiently controlled by oral anti-Parkinson’s medication.1

Speakers

  • Professor Tom Foltynie

    Consultant Neurologist, University College London Hospitals NHS Foundation Trust

  • Professor Peter Jenner

    Emeritus Professor of Pharmacology, King’s College London

  • Dr Amrit-deep Samra

    Consultant Neurologist, University Hospitals Coventry and Warwickshire NHS Trust

Watch the sessions from the webinar below

This promotional webinar was organised and sponsored by Bial

Professor Peter JennerExploiting Dopamine Pharmacology in Parkinson’s Disease

Professor Peter Jenner explained the pharmacological basis of Parkinson’s disease management, highlighting the importance of continuous dopaminergic stimulation and how apomorphine can help overcome limitations of traditional therapies.

Dr Amrit-deep Samra Efficacy and Safety: The Clinical Insights in OFF Episode Management

Dr Amrit-deep Samra focused on real-world management of OFF episodes, demonstrating how Kynmobi offers a fast, effective rescue option with practical guidance on patient selection and use in clinical practice.

Dr Amrit-deep Samra Practical Strategies for Initiation and UK Experience

Dr Amrit-deep Samra shared practical strategies for initiating advanced Parkinson’s therapies, drawing on real-world UK clinical experience to optimize patient transition, dosing protocols, and long-term treatment success.Please note: the patient videos have been removed from the recording to protect the identity of those who consented to recording

Looking for some resources from the webinar?

We have Kynmobi resources available for download, not to be printed. If you'd like some to be sent to you, you can also request physical leaflets by emailing us: ukevents@bial.com

Learn more about access in your area

For support with access in your area or local formulary inclusion, please contact our Market Access Manager to discuss access pathways.

1. KYNMOBI® (Apomorphine hydrochloride). Summary of Product Characteristics. Bial Pharma UK Ltd. Available at: https://www.medicines.org.uk/ (Accessed July 2026).

Basic UK NHS cost: Price per film: £4.81 per film, per dose

Kynmobi Titration Pack x 10 films £48.10, Kynmobi 10 mg sublingual film x 30 £144.30, Kynmobi 15 mg sublingual film x 30 £144.30, Kynmobi 20 mg sublingual film x 30 £144.30, Kynmobi 25 mg sublingual film x 30 £144.30, Kynmobi 30 mg sublingual film x 30 £144.30

HCI, hydrochloride; HCP, healthcare professional; NHS, National Health Service.


WEB-NPD-KM-GB-26-0003

July 2026